Eleftha 440mg Injection

1. Product Introduction

Eleftha 440mg Injection is a targeted cancer therapy that contains Trastuzumab (440mg), a monoclonal antibody used for the treatment of HER2-positive cancers. It plays a crucial role in modern oncology, especially for patients diagnosed with HER2-positive breast cancer and HER2-positive metastatic gastric cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain cancer cells, making them grow more aggressively.

Eleftha 440mg is administered intravenously under the supervision of a trained medical professional. It is either given alone or in combination with other chemotherapy agents depending on the treatment phase, cancer stage, and patient profile. The precision with which Eleftha works has revolutionized the management of HER2-positive cancers, offering patients better control over tumor progression and improving long-term outcomes.

This injection is a prescription-only medicine and is typically given in hospitals or cancer treatment centers where the patient can be monitored closely.

2. Uses of This Medicine

Eleftha 440mg Injection is used in the treatment of:

• HER2-positive Breast Cancer:

  • Early-stage breast cancer (as part of adjuvant therapy after surgery)

  • Metastatic (advanced or stage IV) breast cancer, especially when the tumor overexpresses the HER2 protein

• HER2-positive Metastatic Gastric Cancer:

  • Used in combination with chemotherapy in patients whose tumors express high levels of HER2

• Maintenance Therapy:

  • In some cases, Eleftha is continued as maintenance therapy following initial response to chemotherapy

• Neoadjuvant Setting:

  • Given before surgery to shrink the tumor and make it operable in breast cancer patients

Eleftha is only used in patients whose tumors test positive for HER2 through diagnostic testing. These tests are crucial to ensure the effectiveness of the drug.

3. Benefits of This Medicine

Eleftha 440mg Injection offers a wide range of clinical benefits, especially in targeted cancer treatment. These include:

• Precision Therapy: Trastuzumab targets only HER2-positive cancer cells, sparing normal cells and minimizing overall toxicity.

• Tumor Suppression: It effectively slows down or stops the growth of cancer cells by blocking the HER2 receptor pathway.

• Improved Survival Rates: Studies show that patients treated with Trastuzumab have higher overall survival and disease-free survival, especially in early breast cancer cases.

• Combination Potential: It works well when combined with other chemotherapy agents like paclitaxel, docetaxel, and cisplatin, enhancing overall effectiveness.

• Versatile Usage: Suitable for use across various stages of cancer – neoadjuvant, adjuvant, and metastatic.

• Well-tolerated: Compared to many traditional chemotherapies, Eleftha is generally better tolerated and associated with fewer side effects when monitored appropriately.

Overall, Eleftha 440mg improves patient outcomes, increases quality of life, and provides a more personalized approach to cancer treatment.

4. Side Effects

While Eleftha 440mg Injection is highly effective, it may cause side effects in some patients. These side effects can vary depending on the individual’s health, other medications, and duration of treatment.

Common Side Effects:

• Fever and chills

• Headache

• Nausea or vomiting

• Weakness or fatigue

• Diarrhea

• Cough and respiratory tract infections

• Rash or skin irritation

Serious Side Effects (Require immediate medical attention):

• Heart-related Issues: Trastuzumab may affect heart function, especially in patients with prior heart disease or those taking anthracyclines. Symptoms may include shortness of breath, swelling, or irregular heartbeat.

• Infusion Reactions: Patients may experience fever, chills, breathing difficulty, or allergic reactions during or shortly after the infusion.

• Liver Function Alterations: Abnormal liver function tests have been reported.

• Severe Pulmonary Reactions: Such as interstitial lung disease (rare but serious)

Patients receiving Eleftha 440mg should undergo regular cardiac monitoring (such as echocardiograms) and liver function tests to ensure safety throughout the treatment.

5. Frequently Asked Questions (FAQ)

Q1: How is Eleftha 440mg Injection administered?
A: It is given as an intravenous infusion by a healthcare professional, usually over 90 minutes for the first dose and 30–90 minutes for subsequent doses depending on the patient’s tolerance.

Q2: What tests are required before starting Eleftha?
A: HER2 testing is essential to confirm eligibility. Additionally, cardiac evaluation (like an echocardiogram) is done to assess baseline heart function.

Q3: Can Eleftha be used during pregnancy?
A: No, Eleftha 440mg is not recommended during pregnancy as it may harm the unborn baby. Women of childbearing age should use effective contraception during and for at least 7 months after treatment.

Q4: How long will I need to take Eleftha?
A: Treatment duration varies based on cancer type and response. For early breast cancer, it is typically given for 1 year, while for metastatic cancer, it may be continued until disease progression or unacceptable toxicity.

Q5: Are there any drug interactions with Eleftha?
A: It may interact with other chemotherapy drugs, especially those that affect the heart. Always inform your doctor about all medications, supplements, or herbal products you are using.